Please use this identifier to cite or link to this item:
|Title:||In vitro characterization of a recombinant 32P-phosphorylated anti-(carcinoembryonic antigen) single-chain antibody.||Austin Authors:||Patrick, M R;Chester, K A;Pietersz, Geoffrey A||Affiliation:||Austin Research Institute, Austin Hospital, Heidelberg, Victoria, Australia||Issue Date:||1-Jun-1998||Publication information:||Cancer Immunology, Immunotherapy : Cii; 46(4): 229-37||Abstract:||The major limitations of monoclonal antibody conjugates as therapeutic agents have been their poor tumour targeting, inadequate tumour penetration and immunogenicity. More even and deeper tissue penetration has been demonstrated with smaller antibody fragments. The smaller size and absence of an Fc segment may contribute to a lowered immunogenicity with single-chain antibodies (scFv) and also permit their recombinant engineering and bacterial expression. We describe the successful engineering, expression and pre-clinical characterisation of a phosphorylatable "kemptide" (Leu-Arg-Arg-Ala-Ser-Gly) anti-carcinoembryonic antigen (anti-CEA) scFv (PKS-scFv), for use as a radioimmunotherapeutic agent. Specifically, a yield of 6 mg/l induced culture was obtained. Site-specific phosphorylation was demonstrated without loss of specificity. In vitro assays revealed a selective cytotoxicity of 32P-PKS-scFv for high-CEA-expressing LS-174T cells compared to the low-CEA-expressing HT-29 cells, with a rapid internalisation rate.||Gov't Doc #:||9671146||URI:||http://ahro.austin.org.au/austinjspui/handle/1/13608||URL:||https://pubmed.ncbi.nlm.nih.gov/9671146||Type:||Journal Article||Subjects:||Binding Sites
Immunoglobulin Variable Region.biosynthesis.chemistry.genetics
Tumor Cells, Cultured
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 5, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.